Developing a medication to treat the symptoms of Parkinson’s disease
Prexton Therapeutics is a biotechnology company based in Oss, The Netherlands, with R&D facilities in Geneva, Switzerland. Prexton aims to develop effective and safe drugs to treat the symptoms of Parkinson’s disease, a high unmet need in an indication with limited innovation. Prexton conducts two phase 2 proof of concept trials in Europe and the USA to test for Parkinsonian symptoms and levodopa-induced dyskinesia, respecivtely. Prexton is financed by a broad syndicate of leading European investors.
- CEO François Conquet
- Industry Biotech
- History M&A